Recent issues and developments in antipsychotic use

Psychiatric Clinics of North America: Annual of Drug Therapy

Volumn , Issue , 2001, Pages 209-235

  Miller, A L ^a   Dassori, A ^a   Ereshefsky, L ^a   Crismon, L ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; CLOZAPINE; DIURETIC AGENT; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUPHENAZINE; GLUTAMIC ACID; HALOPERIDOL; HYPNOTIC AGENT; METOCLOPRAMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PROCAINAMIDE; PSYCHOSTIMULANT AGENT; QUETIAPINE; QUINIDINE; RISPERIDONE; SEROTONIN 2 AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; UNINDEXED DRUG; ZIPRASIDONE;

ADVERSE DRUG REACTION; AKATHISIA; ANTICHOLINERGIC EFFECT; ARTICLE; BRAIN CORTEX; BRAIN FUNCTION; CONSTIPATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG SCREENING; DRUG USE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; IN VITRO STUDY; ORTHOSTATIC HYPOTENSION; PREFRONTAL CORTEX; PSYCHOSOCIAL CARE; RECEPTOR AFFINITY; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYMPTOM; TITRIMETRY; URINE RETENTION; VISUAL IMPAIRMENT; WEIGHT GAIN;

EID: 0035204006     PISSN: 10683178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Bodyweight gain induced by psychotropic drugs
2. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles
3. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: Intraindividual variability and plasma level correlations
4. Antipsychotic-induced weight gain: A comprehensive research synthesis
5. Treatment of schizophrenic disorders: Algorithms for acute pharmacotherapy
6. Safety profile of risperidone
7. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence
8. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine
9. Induction of obesity by psychotropic drugs
10. Weight changes during clozapine treatment
11. When symptoms persist: Clozapine augmentation strategies
12. Radioreceptor binding profile of the antipsychotic olanzapine
13. Olanzapine pharmacokinetic and pharmacodynamic profile
14. Canadian Psychiatric Association: Canadian clinical practice guidelines for the treatment of schizophrenia
15. Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia
16. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine
17. The Texas Medication Algorithm Project: Development and implementation of the schizophrenia algorithm
18. Clozapine augmentation: Safety and efficacy
19. Risperidone versus olanzapine in patients with schizophrenia and schizo-affective disorder
20. Schizophrenia
21. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
22. Antipsychotics
23. Psychotropic drug reactions 2000
24. Pharmacokinetic and pharmacodynamic considerations of switching
25. Pharmacokinetics and drug interactions: Update for new antipsychotics
26. Treatment strategies for schizophrenia
27. Managing drug-drug interactions in HIV disease
28. The expert consensus guidelines series: Treatment of schizophrenia
29. Weight gain associated with antipsychotic drugs
30. Diabetic ketoacidosis with olanzapine treatment
31. Serum triglyceride levels in patients treated with clozapine
32. Advisory panel recommends approval of Pfizer's Zeldox for schizophrenia
33. Atypical antipsychotic agents and diabetes mellitus
34. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
35. Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans
36. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: A five year naturalistic study
37. American Psychiatric Association practice guideline for the treatment of patients with schizophrenia
38. Efficacy of aripiprazole in psychotic disorders: Comparison with haloperidol and placebo
39. Pharmacologic treatment of schizophrenia
40. The deadly quartet: Upper-body obesity, glucose intolerance, hypertriyglyceridemia and hypertension
41. Serotonin-dopamine interaction and its relevance to schizophrenia
42. Fast dissociation from dopamine D2 receptors explains atypical antipsychotic action A new hypothesis
43. A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy
44. Relationship between dopamine D2 occupancy, clinical response, and side-effects: A double-blind PET study of first-episode schizophrenia
45. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4 week placebo controlled trial
46. Iloperidone binding to human and rat dopamine and 5-HT receptors
47. The molecular biology of serotonin receptors: Therapeutic implications for the interface of mood and psychosis
48. Weight gain among schizophrenic patients treated with clozapine
49. Translating research into practice: The schizophrenia PORT treatment recommendations
50. Improving treatment for persons with schizophrenia
51. Pharmacotherapy for patients with first-episode, acute, and refractory schizophrenia
52. 2 adrenoreceptors: A key feature of psychotropic neuromodulation?
53. Management of schizophrenia
54. AHFS drug information 2000
55. Treatment of schizophrenia 1999
56. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin 2 pki values
57. The role of serotonin in antipsychotic drug action
58. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms
59. Schizophrenia: How should we look at it?
60. Diabetes mellitus in schizophrenic patients
61. Catalepsy and striato-limbic dopamine metabolism following chronic aripiprazole, risperidone, and haloperidol
62. NMDA receptor hypofunction model of schizophrenia
63. Olanzapine increases weight and serum triglyceride levels
64. A new algorithm for treating schizophrenia
65. Clozapine and associated diabetes mellitus
66. Identification of the major human liver cytochrome P450 isoforms(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions
67. Drug metabolism and atypical antipsychotics
68. Effect of clozapine-quetiapine combination therapy on weight and glycemic control
69. Atypical antipsychotics: Are some more atypical than others?
70. Receptor pharmacology of neuroleptics: Relation to clinical effects
71. St John's Wort: Effect on CYP3A4 activity
72. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors
73. Geriatric psychopharmacology
74. Risperidone compared with new and reference antipsychotic drugs: Vitro and in vivo receptor binding
75. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors
76. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine
77. Olanzapine-induced elevation of plasma triglyceride levels
78. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: A double-blind, placebo-controlled study
79. The unique human receptor binding profile may be related to lack of weight gain with ziprasidone
80. Standards of care and clinical algorithms for treating schizophrenia
81. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
82. Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia
83. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials
84. Weight gain associated with neuroleptic medication: A review
85. Psychopharmacology in the medically ill patient
86. Effect of psychotropic drugs on weight
87. Seroquel restores sensorimotor gating in phencyclidine-treated rats
88. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: Drug monitoring and tolerability data from a prospective clinical trial
89. Schizophrenia and glutamatergic transmission
90. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
91. Treatment guidelines and algorithms
92. Clozapine and weight gain
93. Veterans Health Administration: Clinical guidelines for management of persons with psychosis
94. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study
95. Novel antipsychotics and new-onset diabetes
96. Weight gain associated with novel antipsychotic medications
97. Early treatment and outcome in schizophrenia: A reanalysis of the Camarillo State Hospital data
98. Measuring the quality of outpatient treatment for schizophrenia
99. Antipsychotics linked to weight gain, diabetes